RT Journal Article
SR Electronic
T1 COVID-19 Booster Doses Reduce Sex Disparities in Antibody Responses among Nursing Home Residents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.23.24315989
DO 10.1101/2024.10.23.24315989
A1 Oyebanji, Oladayo A.
A1 Yin, Anna
A1 Sundheimer, Nicholas
A1 Ragavapuram, Vaishnavi
A1 Shea, Patrick
A1 Cao, Yi
A1 Chan, Philip A.
A1 Nanda, Aman
A1 Tyagi, Rohit
A1 Raza, Sakeena
A1 Mujahid, Nadia
A1 Abul, Yasin
A1 Balazs, Alejandro B.
A1 Bosch, Jürgen
A1 King, Christopher L.
A1 Klein, Sabra L.
A1 Gravenstein, Stefan
A1 Canaday, David H.
A1 Wilson, Brigid M.
YR 2024
UL http://medrxiv.org/content/early/2024/10/23/2024.10.23.24315989.abstract
AB Background Data suggests that antibody responses following COVID-19 vaccines are a correlate of protection. Some studies, including the clinical trials of COVID-19 mRNA vaccines, did not stratify and evaluate whether antibody responses to COVID-19 vaccines differed between the sexes or with aging. This gap in research is particularly relevant for older populations such as nursing home residents (NHR). We hypothesized that sex differences in vaccine-induced antibody responses may intersect with age and be diminished among older adults residing in nursing homes.Methods We analyzed serum samples from 638 NHRs collected serially after the primary two-dose series and three subsequent booster doses of mRNA SARS-CoV-2 vaccinations. We analyzed anti-Spike IgG and neutralizing antibody titers to the Wuhan and Omicron BA.4/5 variant strains. Mixed-effects models predicting log-transformed titers were estimated to compare responses across vaccine doses, focusing on sex-differential responses. For detected post-dose sex differences, additional sample times were analyzed to assess the duration of the difference.Results Following the primary series, female NHRs with a prior history of SARS-CoV-2 infection had significantly higher Wuhan anti-Spike antibodies and neutralizing antibody titers than male NHRs with differences persisting up to nine months post-vaccination. Subsequent monovalent booster doses and a bivalent booster dose eliminated this disparity. We did not detect any differential response to the Omicron BA.4/5 variant.Conclusions The blunting of sex differences in antibody response observed following the primary series by the 1st booster dose underscores the importance of booster vaccination in this population.Competing Interest StatementStefan Gravenstein (S.G) and David H. Canaday (D.H.C) receive investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur to study influenza vaccines. S. G. also consults for GlaxoSmithKline, Janssen, Moderna, Novavax, Pfizer, Sanofi, Seqirus, and Vaxart and has served on the speakers' bureaus for Seqirus and Sanofi.Funding StatementThis work was supported by NIH AI129709-03S1, CDC 200-2016-91773, U01 CA260539- 03, and VA BX005507-0. The sponsors had no role in the decision for publication or the message presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Western-Copernicus Group Institutional Review Board (WCG IRB) with the protocol number STUDY20211074. All participating residents or their legally authorized representatives provided informed consent to be enrolled. The study is in accordance with the 1964 Declaration of Helsinki and its later amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe de-identified dataset and related codes for analysis will be made available to researchers upon request after peer reviewed publication. Requests for data should be addressed to the corresponding authors.NHRNursing Home ResidentCOVID-19Coronavirus Disease 2019WCGWestern-Copernicus GroupSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2mRNAMessenger Ribonucleic AcidRBDReceptor Binding DomainPCRPolymerase Chain ReactionBAUBinding Antibody UnitAUArbitrary UnitLLDLower Limit of DetectionGMTGeometric Mean TiterCIConfidence Interval